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1009-84 Implications of Smoking Status on the Response to 
Therapeutic Angiogeneois  In Peripheral Artery Disease: 
Findings From the Therapeutic Angiogenesis With FGF- 
2 for Intermittent Cleudication ('I'RAFRC) Trial 
Joroe F. Saucedo. Mohammed M. Moursi, R. D. Anderson, Farrell O. Mendelsohn, 
James B. Hermiller, Robert Federici, James Zidar, Adam B. Greenbaum, Thomas Moon, 
M. J. Whitahouse, Brian H. Annex, Robert J. Lederman, University of Arkansas for 
Medical Sciences, Little Rock, Arkansas, National Heart Lung and Blood Institute, 
Bethesda, Maryland. 
Background: Fibroblast growth factor-2 (FGF-2) is a potent angiogenic agent in multiple 
preclinical models. A single intra-arterial infusion of 30 mcg/kg rFGF-2 was associated 
with significant improvement in peak walking time (PWT) at 90 days in a phase II, ran- 
domized, placebo-controlled trial in patients with moderate to severe claudication (TRAF- 
FIC). Nicotine has angiogenic activity. A pro specified subgroup analysis was based on 
baseline smoking status. 
Methods: The primary endpoint, change in PWT from baseline to 90 days, was analyzed 
by treatment group (pooling FGF-2 groups) and smoking status at enrollment. 
Results: Current smokers were 38% of the placebo group and 23% of FGF-2 groups. 
Baseline PWTs were comparable among groups. Current smokers had greater increases 
in PW'I" both in placebo and FGF-2 groups compared with non-smokers. 
Conclusion: Non-smokers appeared to derive significantly greater benefit from rFGF-2 
than smokers, despite larger PWT increases in smokers assigned either placebo or FGF- 
2. The large difference between the two placebo groups warrants further evaluation. 
Smoking status needs to be considered in the design of future angiogenesis tudies. 
Variable Currant.Smoker Non-Smoker 
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Placebo All FGF-2 Placebo All FGF-2 
N (evaluable)= 23 25 35 91 
PWT Baseline (min) 5.23+~?..35 5.46+2.98 5.37+~2.69 5.46-+.2.62 
~PWT at 90 d (min) 1.25+2.87 2.17_+1.68 0.18+~2.02 1.54_+2.81 
95% CI around ,~PWT [-0.62, 3.12] [0.16, 4.18] [-0.81, 1.16] [.85, 2.23] 
P-value vs placebo 0.46 0.016 
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1010-85 Insulin Resistance Is Associated With Left Ventriculer 
Remodeling: The Framingham Heart Study 
Martin K. Rutter, Helen Parise, Martin G. Larson, Emelia J. Benjamin, Daniel Levy, 
James B. Meigs, Richard W. Nesto, Peter W. Wilson, Ramachandran S. Vasan, NHLBI's 
Fremingham Heart Study, Framingham, Massachusetts, Boston Universi~ Boston, 
Massachusetts. 
BACKGROUND: Increased left ventdcular mass (LVM) is a potent cardiovascular isk 
factor but its pathogenesis is inadequately understood. Though insulin resistance has 
been implicated in the development of left ventricutar (LV) hypertrophy and altered geom- 
etry (LV remodeling), prior studies have yielded inconsistent results. 
METHODS: We examined how normal glucose tolerance (NGT), impaired glucose toler- 
ance (IGT) impaired fasting glucose (IFG), and diabetes (World Health Organization 
1998) were related to echocardiogrephic LV measurements in 2637 Fremingham Off- 
spdng Study subjects (1520 women, mean age 53 yrs). We also examined the relations 
of insulin resistance (assessed by fasting insulin and homeostasis model, HOMA-IR) and 
LV measures. 
RESULTS: After adjusting for covariates, LV mass and wall thickness were greater 
across WHO categories of worsening glucose tolerance (p<0.04 for trend across catego- 
ries for both). In subjects with NGT (N=2033), LV mass, wall thickness and relative walt 
thickness increased across quartiles of fasting insulin (Table) and HOMA-IR. Adjustment 
for BMI attenuated these relations, suggesting that LV effects may be partially mediated 
through increasing BMI across quartiles of fasting insulin. 
Quartiles of fasting insutin P (trend)* 
Q1 Q2 Q3 Q4 
LV Mass (g) 156.8 159.9 156.9 162.2 0.032 
LV wall thickness (cm)** 1.86 1.88 1.87 1.90 0.005 
LV internal diameter (cm) 4.73 4.76 4.72 4.75 0.970 
Relative wall thickness 0.396 0.396 0.400 0.403 0.042 
*adjusted for age, sex, height, systolic BP, and heart rate; **sum of interventdcular 
septum and LV posterior wall 
CONCLUSIONS: LV remodeling increased with worsening glucose tolerance. Within the 
NGT group, insulin resistance was associated with greater LV remodeling. Additional 
research is needed to examine if modifying insulin resistance favorably influences LV 
remodeling. 
1010-86 Insulin Improves Alveolar Gas Exchange in Patients 
With Type 2 Diabetes and Heart Failure 
Marco Guazzi, Roberto Brambilla, Stefano DeVita, Maurizio D. Guazzi, Institute of 
Cardiology, University of Mi/ano, Mi/ano, Italy. 
Background, Chronic heart failure (CHF) (hydrostatic stress) and, less commonly, dia- 
betes mellitus (basal laminae thickening), can damage the alveolar-capillary membrane. 
We probed whether coexistence of diabetes worsens pulmonary gas transfer in CHF, 
and whether insulin improves this effect. 
Methods and Results. 15 controls and 25 CHF patients were investigated. 11 patients 
(group 1) were normoglycemic and 14 (group 2) had type 2 diabetes. Cardiac function, 
pulmonary diffusion (DLco) and its subdivisions, D M (membrane conductance) and V c 
(pulmonary capillary blood), were assessed at rest. In patients, measurements were 
repeated following infusion of 50 ml saline + regular insulin (10 IU), or saline alone, in two 
consecutive days (random crossover design). 
At rest, compared to controls, reduction in ejection fraction (EF) and elevation in wedge 
pulmonary pressure (wpp) were similar in groups 1 and 2; DLco (percent normal and 
absolute values), D a and DM/alveolar volume were more reduced (p < 0.01 ), and DLco/ 
D u was more raised (p < 0.01) in group 2. Saline in groups 1 and 2, and insulin in group 
1 were ineffective. Insulin in group 2 significantly (p<0.01) augmented DLco (+17%) and 
D M (+26.5%), reduced DLco/D M (from 74+8.8 % to 63+9.9%) and did not affect EF and 
wpp. There was no correlation between changes in D u and those in blood sugar. 
Conclusions. Diabetes potentiates gas diffusion impairment in CHI£ Insulin counteracts 
this effect by improving the alveolar-capillary conductance. We suggest that insulin 
releases substances (nitric oxide, vasedilating prostaglandins) active on the "leacky' pul- 
monary capillaries, or enhances sodium absorption from alveolar lumen (glucose-sodium 
co-transport mechanism), thus shortening the distance between blood and alveoli, and 
facilitating as transfer. 
1 010-87 Long-Term Cardiovascular Effects of Troglitazone on 
NondiabeUc Individuals With Insulin Resistance: 
Double Blind Prospective Randomized Study 
Dimitrios Stakos. Elizabeth Sparks, Dara Schuster, Kwame Osei, Charles Wooley, 
Harisios Boudoulas, Ohio State University Medical Center, Columbus, Ohio. 
Background: The beneficial effect of oral hypoglycemic agents in diabetic patients is 
mainly attributed to glycemic control. While it has been suggested that treatment with oral 
antidiabetic Troglitazone (TGL) or similar agents may prevent cardiovascular complica- 
tions in non-diabetic individuals with insulin resistance, the long-term cardiovascular 
effects of these agents remains unknown. 
Methods: In 137 African-American offspring of type 2 diabetic parents with normal glu- 
cose tolerance test (OGTT) and insulin resistance, TGL 200 mg/d (n = 40) or identical 
placebo tablets (n = 97) were given for 24 months. Insulin sensitivity; total, high density 
lipoprotein, low density lipoprotsin cholesterol, and triglycarides; brachial artery blood 
pressure (sphygmomanometry); left ventricular diameters and mass (echo); and aortic 
pulse wave velocity (PWV, carotid to femoral artery, Doppler) were measured at baseline, 
at 12 and at 24 months after randomization. 
Results: No significant changes in OGTT, insulin sensitivity or lipids profile were 
observed in either group during the follow-up period. PWV in the placebo group did not 
change significantly (baseline 9.6 ± 2.4 m/sac, 12 months 10.7 ± 2.4 m/sec, 24 months 
10.1 ± 2.6 m/sac). In contrast, PWV increased significantly in the TGL group (baseline 
8.9 ± 1.6 m/sac, 12 months 9.9 ± 2.1 m/sec, 24 months 10.7 ± 2.3 m/sac, ANOVA p = 
0.0002). Compared to baseline, PWV was increased both at 12 (p<0.01) and at 24 
months (p<0.001). Systolic blood pressure decreased slightly in the control group, and 
remained unchanged in the TGL group. The increase in PWV is consistent with a 
decrease in the elastic properties of the aorta. LV diameters, % shortening of the LV 
internal diameter and LV mass, did not change significantly in either group dudng the fol- 
low-up period. 
Conclusion: Long-term administration of TGL to non-diabetic African-Americans with 
insulin resistance may decrease the elastic properties of the aorta. Thus, long-term ther- 
apy with TGL or similar agents for the prevention of cardiovascular complications to non- 
diabetic individuals with insulin resistance needs to be critically evaluated. 
1010-88 Estrogen Improves Arterial Stiffness in 
Postmenopeusal  Diabetic Women 
Amit Nussbacher. Claudia Sztejnsznajd, Elizabeth Silva, Otavio C. Gebara, Jo~o B. 
Serro-Azul, Humberto Pierd, Silvia Lage, Giuseppe Rosano, Mauricio Wajngarten, Jos~ 
Antonio E Ramires, Heart Institute (InCor), University of Sag Paulo Medic, el School, S~o 
Pau/o, Brazil, Division of Endocdno/ogy, University of S~o Paulo Medical School, S&o 
Pau/o, Brazil 
Diabetes is associated with increased cardiovascular morbidity and mortality. The effects 
of estrogen replacement herapy on arterial compliance in postmenopausal diabetic 
women has not been fully investigated. The goal of this study was to evaluate the acute 
and chronic effects of estrogen on artedal stiffness in 14 postmenopausal women with 
type 2 diabetes aged 56±4 years and with a body mass index of 28.2±2.5 kg.m-2. 
Patients underwent noninvasive assessment of two indices of arterial stiffness: cartotid 
artery augmentation index (AGI) and carotid-femoral pulse wave velocity (PWV). Mea- 
surements were performed at baseline (BL), 20 minutes after 1.25 mg of intravenous 
conjugated equine estrogen (CEE) (ACUTE), and after 4 months of 0.625 m~/day oral 
CEE (CHRONIC). As shown in table, mean arterial pressure (MAP), heart rate (HR) and 
AGI were not changed whereas PWV was reduced both acute and chronically (*=p<0.05 
vs. BL). 
Therefore, in postmenopausal diabetic women with stiff vasculature (elevated baseline 
